Barrington Research Has Strong Forecast for MMSI Q3 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Barrington Research increased their Q3 2025 earnings per share (EPS) estimates for Merit Medical Systems in a note issued to investors on Wednesday, January 29th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings per share of $0.96 for the quarter, up from their previous forecast of $0.95. Barrington Research has a “Outperform” rating and a $115.00 price objective on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.82 EPS and FY2026 earnings at $4.30 EPS.

A number of other analysts have also issued reports on the company. Needham & Company LLC raised their target price on Merit Medical Systems from $109.00 to $122.00 and gave the company a “buy” rating in a report on Wednesday. Canaccord Genuity Group increased their price target on shares of Merit Medical Systems from $127.00 to $128.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler restated an “overweight” rating and set a $116.00 price objective (up previously from $114.00) on shares of Merit Medical Systems in a report on Wednesday. Wells Fargo & Company upgraded shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $103.00 to $120.00 in a research note on Wednesday, December 11th. Finally, StockNews.com lowered Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.80.

Merit Medical Systems Trading Up 1.7 %

Merit Medical Systems stock opened at $110.29 on Thursday. Merit Medical Systems has a 52 week low of $70.70 and a 52 week high of $111.27. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The firm has a market capitalization of $6.43 billion, a PE ratio of 54.06, a PEG ratio of 2.34 and a beta of 0.85. The business’s 50-day simple moving average is $101.36 and its 200-day simple moving average is $97.04.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The firm had revenue of $339.85 million for the quarter, compared to the consensus estimate of $334.60 million. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS.

Institutional Trading of Merit Medical Systems

Large investors have recently made changes to their positions in the business. Barclays PLC grew its holdings in Merit Medical Systems by 305.4% during the 3rd quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after acquiring an additional 84,923 shares during the last quarter. Van ECK Associates Corp bought a new stake in shares of Merit Medical Systems during the third quarter valued at approximately $718,000. Fisher Asset Management LLC increased its holdings in shares of Merit Medical Systems by 3.2% in the third quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock valued at $21,910,000 after purchasing an additional 6,837 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Merit Medical Systems by 85.6% in the third quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock valued at $56,921,000 after purchasing an additional 265,648 shares in the last quarter. Finally, AMI Asset Management Corp raised its position in Merit Medical Systems by 28.7% in the 4th quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier’s stock worth $3,196,000 after purchasing an additional 7,367 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, Director F. Ann Millner sold 12,500 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.55, for a total value of $1,269,375.00. Following the transaction, the director now directly owns 32,391 shares in the company, valued at $3,289,306.05. The trade was a 27.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Raul Jr. Parra sold 29,646 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now directly owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. The trade was a 64.44 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.